论文部分内容阅读
目的:观察厄贝沙坦在老年肥胖高血压患者中的疗效。方法:入选老年肥胖高血压患者26例,予厄贝沙坦降压治疗,观察厄贝沙坦对血糖、血胰岛素、血脂联素、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、TC、TG及24h血压监测及脉搏波速率(PWV)的影响。结果:与治疗前相比,经厄贝沙坦治疗24周后,患者除血压降低外,胰岛素敏感指数升高[(-4.54±0.07)∶(-4.01±0.09)],P<0.05;血脂联素水平升高[(6.57±0.64)∶(8.27±0.81)mg/L],P<0.05;IL-6和PWV水平下降[(2.09±0.37)∶(1.36±0.25)ng/L,(1 754±64)∶(1 532±81)m/s],均P<0.001。相关分析显示,厄贝沙坦治疗前后PWV变化与收缩压、舒张压下降呈明显相关,而胰岛素敏感指数、血脂联素和IL-6的变化与其降压作用无相关性。结论:厄贝沙坦对老年肥胖高血压患者,具备独立于降压作用以外的改善胰岛素抵抗、减轻炎症反应的作用。
Objective: To observe the efficacy of irbesartan in elderly patients with obesity and hypertension. Methods: A total of 26 obese hypertensive patients were enrolled in this study. Irbesartan was taken as the antihypertensive treatment. The effects of irbesartan on blood glucose, blood insulin, serum adiponectin, interleukin-6 (IL-6) (Hs-CRP), TC, TG and 24h blood pressure monitoring and pulse wave velocity (PWV). Results: Compared with those before treatment, the serum insulin sensitivity index increased (-4.54 ± 0.07) :( -4.01 ± 0.09), P <0.05 after 24 weeks treatment with irbesartan, The level of IL-6 and PWV was significantly lower than that of control group ([(6.57 ± 0.64) vs (8.27 ± 0.81) mg / L], P <0.05; 1 754 ± 64): (1 532 ± 81) m / s], all P <0.001. Correlation analysis showed that the changes of PWV before and after irbesartan treatment were significantly correlated with the decrease of systolic pressure and diastolic pressure. There was no correlation between the changes of insulin sensitivity index, blood adiponectin and IL-6 and its antihypertensive effect. Conclusion: Irbesartan has the effect of improving insulin resistance and relieving inflammatory reaction independent of antihypertensive effects in elderly obese hypertensive patients.